A gene expression-based immune signature for lung adenocarcinoma prognosis
ConclusionsThe identified DEG features may serve as potential biomarkers for prognosis prediction of LUAD patients and immunotherapy. Based on that assumption, we identified a gene expression-based immune signature for lung adenocarcinoma prognosis.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Lung Cancer | Study